r/HUMACYTE

Sorry in advance for the rant but back to back 52 week lows have led me frustrated and upset, with contradicting info from mgmt....clinical trials slip and commercial negotiations are complicated but we, as shareholders, often cannot tell whether a milestone slipped for a concrete reason, was deprioritised, or is still actively progressing.

If anyone wants to help me reach out Scott Coward (he has a substantial holding), or another director, that'd be helpful.

1. KSA: What happened after the exclusivity period?

In March, Humacyte announced a binding $1.475 million purchase commitment alongside a JV negotiation exclusivity window that expired on July 2, 2026. Has the evaluation program officially commenced with delivered units, and are definitive joint venture or licensing negotiations still actively progressing?

Riyad airport bombed just yesterday, the conflict with Houthis is live....yet, nothing from KSA counterparties or HUMA.

I would also welcome an explanation of such partnerships are now being managed following Rick McElheny's departure at exactly the same time the exclusivity expired. His departure alone does not prove that the KSA opportunity has stalled, but investors should understand whether responsibility for the discussions has changed.

2. CTEV/CABG: What is the actual enrolment date?

On 27 July, after FDA acceptance of the IND, the company said the Phase 2a CABG study was expected to start and finish "this quarter", Q3 2026  (only 10 patients), consistent with page 8 of the corporate presentation.

Last month (16 September H.C. Wainwright conference), Dale described initiation more broadly as expected "sometime in 2026," with the first three patients enrolled in a staggered manner, two months apart.

Public records for trial NCT07730528 show no enrolment. Has enrolment started? If not, why?

 3. PAD: What happened to the Phase 3 trial ?

At the 15 June virtual investor event, Laura indicated that a Phase 3 PAD trial could launch in July, August, or September (coherent with page 8 of corporate presentation stating that PAD Phase 3 trial as "under design.")...since then, crickets.

Company had meeting with FDA in late August 2026: Is the trial protocol actively being finalized with the FDA, or has the program been paused to preserve capital for the dialysis sBLA?

 4. Adolescent trauma: What is the purpose and priority of V019?

A new study, NCT07762313 / CLN-PRO-V019, has been published and is enrolling and we have no idea what this is for. Not a single comment from mgmt or PR... what is the study intended to support: a future paediatric/adolescent label expansion, evidence for military use, or another regulatory requirement?

 5. Rick McElheny: What happened to corporate partnerships?

Rick McElheny was let go as SVP of Business Development only 7 months into the job, coincidently at the same time the KSA JV exclusivity came to an end.

His role was important to "expand corporate collaborations to accelerate development and commercialisation of the company's broad regenerative-medicine pipeline" including CABG and the BVP for Type 1 diabetes.

What happened to the corporate-partnership strategy he was hired to advance? Were discussions under way for CTEV/CABG or the BioVascular Pancreas? Are any of those discussions continuing, and who now owns business development (assuming it's still a priority / part of the strategy)?

 6. DoD: Did the anticipated purchase happen?

I have written a few posts already so will not digress too much.

On the 13 May 2026 Q1 earnings call, Laura described the effort as a collaboration among Humacyte, the DoD, and surgeons at several military treatment facilities. She said, "We are hoping to have this purchase completed by around September" and explained that the purchase would support surgeon training and clinical use at different MTFs.

Was the $1m budget for FY26 consumed by September? If not, what remains outstanding, and is the plan still to support training and clinical use across multiple MTFs?

 7. Fresenius: Why exit before the dialysis catalyst?

Fresenius Medical Care's filing said its decision to sell its entire stake in the company (after having invested $175m and held to its investment for 8 years) was: "Consistent with FME AG's FME Reignite strategy implementation and the strategic focus previously outlined to investors."

But the timing deserves a much more direct answer: Why would a dialysis corporate investor sell its entire remaining equity stake 8 months before a catalyst that could materially affect the dialysis opportunity? Did Fresenius receive any information that led it to reduce exposure before the filing or approval? Did Laura running the company into the ground with Dale kill their hopes?

 8. Management ownership: Put money where your mouth is

Laura said at the recent September HCW investor conference that the company is "extremely undervalued." If management genuinely believes that, the most credible response is not another explanation of the market's misunderstanding, it is insider buying at current levels. Why is management not buying shares?

This hospital is in my area. I should be over there next week. I’ll try to get some info from folks at the hospital. I’m a rep in an unrelated specialty, maybe I can see what they paid for it. Very curious how many are being used nationwide.

I know this has been a long time coming, but I just still really can't believe the leadership has driven this stock so low with horrible choices and bad planning. It's just such a shame.

Original article -->Associated Press, Oct 5, 2026: Takeaways from AP report on Iranian attack in Kuwait that killed 6 US soldiers and wounded dozens

The Iranian drone strike at Port Shuaiba, which reportedly killed six US soldiers and injured dozens, underscores the increasing importance of forward medical readiness...despite all the technological changes reshaping modern conflict, serious traumatic injuries still require immediate treatment on the ground.

The AP report the severity of the wounds sustained by Army Lieutenant Colonel Arturo Lincón, who was struck by shrapnel that penetrated his jaw and neck, severed an artery, and lodged in a vertebra.

Despite what many have said in this SubReddit about the rapid evolution of warfare (involving drones, missiles, cyber capabilities, and electronic warfare...instead of boots on the ground), serious vascular trauma remains a critical battlefield problem.

To be clear, the article does not explicitly state that Symvess was used in this specific case, yet it highlights the precise type of injury for which an off-the-shelf vascular conduit could be relevant when conventional vein harvest is not feasible or time is of the essence (assuming there is medical personel on the ground / nearby)

Symvess recent extension of its refrigerated shelf life to 36 months for trauma indications is significant from a military-readiness perspective, as it potentially facilitates more practical long-term pre-positioning and stock rotation (which I wrote about here: https://www.reddit.com/r/HUMACYTE/comments/1vh5oz8/comment/p8blza6/?)

The company has recently published a new V019 adolescent trauma trial (starting in September) which represents an incremental platform extension for trauma and Symvess: https://clinicaltrials.gov/study/NCT07762313?term=Humacyte&viewType=Card&page=2&rank=12

Enrolling just 10 patients with completion slated for late 2028, it tests whether the FDA-approved 6 mm conduit functions in sexually mature teens facing severe arterial injuries when a vein graft isn't an option.

Restricting enrollment to Tanner Stage 5 patients is a logical move, as it targets individuals who have essentially reached full physical maturity, avoiding potential vessel size mismatch as the patient grows.

If successful, the study would broaden the trauma label, add another application for the existing production line, and reinforce Symvess's primary selling point as an immediate, off-the-shelf biologic alternative when harvesting a vein is unfeasible.

Just published yesterday: https://media.defense.gov/2026/Sep/30/2004009303/-1/-1/1/ESTABLISHMENT-OF-FORTRESS-AMERICA-AS-A-DEPARTMENT-OF-WAR-PROGRAM-FOR-THE-DEFENSE-OF-THE-AMERICAN-HOMELAND.PDF

Though not direct evidence of an imminent DoD order for Symvess, FORTRESS America is worth watching as a potentially favorable strategic signal.

Yesterday, Peter Hegseth explicitly called for deeper strategic reserves of munitions, fuel, medicine and blood so the U.S. can keep fighting if wartime supply lines break...which I assume is relevant for off-the-shelf vascular conduit that can be kept in reserve and deployed when needed. The recent extension of refrigerated shelf life from 18 to 36 months, which makes a centralized strategic stockpile much more practical and reduces expiry/waste risk.

There’s also a broader military-medical trend toward exactly this kind of resilience thinking: Army’s 2026 work on forward resuscitation explicitly identifies large-scale combat operations and logistics-constrained environments as drivers for new medical-stockpile solutions, while DARPA is pursuing shelf-stable blood technologies specifically because cold-chain logistics are problematic in austere environments (though Symvess still needs refrigeration at 2–8°C....)

I know it's indirect signalling at best but Symvess is at least aligned with that need and DoD / DoW order could come rather soon.